Insmed | INSM - Ordinary Share Capital

Stock Price
146.44
Daily Change
1.34 0.92%
Monthly
29.72%
Yearly
103.90%
Q3 Forecast
143.90

Insmed reported $211.11M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 2.48B
Cash and Equivalent USD 1.28B
Cost of Sales USD 29.34M
Current Assets USD 2.08B
Current Liabilities USD 311.68M
Debt USD 564.1M
EBIT USD -253.88M
EBITDA USD -297.13M
Employees 1.27K
EPS Earnings Per Share USD -1.7
Equity Capital and Reserves USD 1.25B
Gross Profit on Sales USD 78.08M
Interest Expense on Debt USD 21.25M
Interest Income USD 0
Loan Capital USD 560.95M
Market Capitalization USD 21.64B
Net Income USD -321.69M
Operating Expenses USD 361.29M
Operating Profit USD -253.88M
Ordinary Share Capital USD 211.11M
Pre-Tax Profit USD -320.44M
Sales Revenues USD 107.4M
Selling and Administration Expenses USD 76.44M
Stock USD 107.61M
Trade Creditors USD 78.35M
Trade Debtors USD 55.03M

Ordinary Share Capital Change Date
BioMarin Pharmaceutical USD 192M 191.81M Jun/2025
Cytokinetics USD 119.6M 119.48M Jun/2025
DBV Technologies USD 136.76M 125.11M Jun/2025
Dynavax Technologies USD 117.23M 117.11M Jun/2025
Gilead Sciences USD 1.24B 3M Jun/2025
Insmed USD 211.11M 209.29M Jun/2025
Novartis USD 1.94B 1.14B Jun/2025
Regeneron Pharmaceuticals USD 106.4M 106.4M Jun/2025
Sarepta Therapeutics USD 97.71M 97.7M Jun/2025
Ultragenyx Pharmaceutical USD 96.35M 2.45M Jun/2025
Vertex Pharmaceuticals USD 256.3M 253.7M Jun/2025